Risk factors and their relationship to prognosis in myelodysplastic syndromes

Leukemia Research

Volumn 22, Issue SUPPL. 1, 1998, Pages

  Greenberg, Peter L ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

International prognostic scoring system; Myelodysplastic syndromes; Prognosis; Risk factors

Indexed keywords

CYTOKINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; CONFERENCE PAPER; CYTOGENETICS; CYTOPENIA; HUMAN; MYELODYSPLASTIC SYNDROME; ONCOGENE; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCORING SYSTEM; TUMOR SUPPRESSOR GENE;

HUMANS; KARYOTYPING; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0031817138     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00040-X     Document Type: Conference Paper

References (33)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189.
2. Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE, Brunning RD. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988;68:189.
3. Pierre R, Catovsky D, Mufti G, Swansbury G. Clinical cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 1990;44:15.
4. Morel P, Hebbar M, Lai JL, Duhamel A. Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7:1315.
5. Toyama K, Ohyashiki K, Yoshida Y, Abe T. Clinical implications of chromosomal abnormalities in 401 patients with MDS: a multicentric study in Japan. Leukemia 1993;7:499.
6. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985;59:425.
7. Sanz GF, Sanz MA, Vallespi T, Canizo M. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:395.
8. Aul C, Gatterman N, Heyll A, Germing U. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52.
9. Oscier D. Myelodysplastic syndromes. Bailliere's Clin Haematol 1987;1:389.
10. Greenberg P, Taylor K, Larson R, Koeffler P, Negrin R, Saba H, et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes. Blood 1993;82(Suppl 1):196a.
11. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton D, Gralnick H, et al. The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chhronic myelomonocytic leukemia. Br J Haematol 1994;87:746.
13. Mitelman F, editor. ISCN: An International System for Human Cytogenetic Nomenclature. Basel: Karger, 1995.
14. Wattel E, Lai JL, Hebbar M, Preudhomme C, et al. De novo myelodysplastic syndrome with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leukemia Res 1993;17:921.
15. Campbell LJ, Garson OM. The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders. Leukemia 1994;8:67.
16. Jacobs RA, Corbleet M, Vardiman J, Larson R, LeBeau MM, Rowley JD. Prognostic implictions of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986;67:1765.
17. Sokal G, Michaux JL, Van den Berghe H, Cordier A, Rodhain J, Ferrantr A, et al. A new hematologic syndromes with a distinct karyotype: the 5q-chromosome. Blood 1975;46:519.
18. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q-anomaly. Cancer Genet Cytogenet 1985;17:189.
19. United Kingdom Cytogenetics Group. Loss of the Y chromosome from normal and neoplastic bone marrows. Genes Chrom Cancer 1992;5:83.
20. Samuels BL, Larson RL, LeBeau MM, Daly KM, Bitter MA, Vardiman JW, et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988;2:79.
21. Greenberg P, Cox C, Bennett JM. Blood (Letter) 1997;90:4233.
22. Second International Workshop on Chromosomes in Leukemias. Chromosomes in preleukemia. Cancer Genet Cytogenet 1980;2:108.
23. Borgstrom GH. Cytogenetics in myelodysplastic syndromes. Scand J Haematol 1986;36(Suppl 45):74.
24. Sucio S, Kuse R, Weh, Hossfeld. Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome. Cancer Genet Cytogenet 1990;44:15.
25. Sole F, Prieto F, Badia L, et al. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 1992;64:12.
26. Kaneko Y, Naseki N, Takasaki N, et al. Clinical and hematologic characteristics in AML with 11q23 translocations. Blood 1986;67:484.
27. Berger R, Flandrin G, Bernheim A, et al. Cytogenetic studies in 519 consecutive de novo AML patients. Cancer Genet Cytogenet 1987;29:9.
28. Second MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic working classification of AML. Cancer Genet Cytogenet 1988;30:1.
29. Greenberg P, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, et al. Letter. Application of the international prognostic scoring system for MDS. Blood 1997;90:2844.
30. Cortes J, Kantarjian H, O'Brien S, Keating M, Pieerce S, Freireich EJ, Estey E. Clinical and Prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia 1995;9:115.
31. Cortes J, O'Brien S, Kantarjian H, Cork A, Strass S, Freireich EJ, et al. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 1994;8:2174.
32. Taj A, Ross F, Vickers M, Choudhury D, Harvey J, Barber J, et al. t(8;21) myelodysplasia, an early presentation of Mx AML. Br J Haematol 1995;89:890.
33. Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very low-risk group using standard mortality ratio techniques. Br J Haematol 1996;94:116.